Aytu BioScience Inc. divested Primsol, an oral antibiotic solution for urinary tract infections, to Allegis Holdings LLC for nearly $1.8 million in cash.

The deal closed March 31. Primsol will remain on the market during the transition.

The sale is intended to support the ongoing U.S. launch of Natesto, an FDA-approved nasal formulation of testosterone for men with hypogonadism, or low testosterone levels, while the company initiates commercial efforts outside the U.S. for MiOXSYS, a novel, rapid semen analysis system used to improve the management of male infertility caused by oxidative stress.